Shogo Urabe

Shogo Urabe

Auto-generated profile, based on publicly available information

Shogo Urabe

Department of Pathology, Oita Prefectural Hospital, Oita, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2021 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
MSMasuho Saburi
Masuho Saburi
YSYoshio Saburi
Yoshio Saburi
KKKatsuya Kawano
Katsuya Kawano
RSRyuichi Sato
Ryuichi Sato
SUShogo Urabe
Shogo Urabe
EOEiichi Ohtsuka
Eiichi Ohtsuka

1 December 2012 in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Verified
Journal Article
Closed access
NYNaomi Yada
Naomi Yada
KKKenji Kashima
Kenji Kashima
TDTsutomu Daa
Tsutomu Daa
SUShogo Urabe
Shogo Urabe
YKYoshiyuki Kondo
Yoshiyuki Kondo
SYShigeo Yokoyama
Shigeo Yokoyama

10 February 2012 in Endoscopy
Verified
Journal Article
Open access
PDF file
YNY. Nakagawa
Y. Nakagawa
Kazunari MurakamiKazunari Murakami
Kazunari Murakami
YHY. Hirashita
Y. Hirashita
RORYO OGAWA
RYO OGAWA
AHA. Hisamatsu
A. Hisamatsu
TFT. Fujioka
T. Fujioka
A 61-year-old woman was referred to our hospital in November 2011 for treatment of chronic diarrhea and refractory gastrointestinal ulcers. Her medical history included thymoma (resected at age 44) accompanied by hypogammaglobulinemia and pure red cell aplasia (PRCA), and a distal gastrectomy for gastric ulcer (refractory to proton pump inhibitor treatment and Helicobacter pylori eradication). On the patient’s admission, laboratory examination revealed severe hypogammaglobulinemia, absence of peripheral B cells, CD4+ T-cell lymphopenia, and inverted CD4 /CD8+ T-cell ratio. Pathogenic bacteria, cytomegalovirus, and human immunodeficiency virus tests were negative. From these results and her medical history, the patient was diagnosed with Good syndrome with PRCA, and was treated with intravenous immune globulin (IVIG) every 2 weeks. At 2 months later, her immune globulin level had increased to normal. Previously upper and lower gastrointestinal endoscopy had shown an ulcer at the greater curvature ([Fig. 1 a]), and similar multiple ulcers at the ileocecum and the terminal ileum on admission ([Fig. 1 c]). Histopathological analysis of the biopsy specimens from these lesions showed a lack of plasma cells in the lamina propria, epithelial apoptosis, and increased intraepithelial lymphocytes (IELs) ([Fig. 2]). Similarly, 2 months after initiation of IVIG treatment, these lesions were markedly improved ([Fig. 1 b, d]), and the epithelial apoptosis and IELs had disappeared. Good syndrome is defined as thymoma with adult-onset immunodeficiency, and is characterized by hypogammaglobulinemia, low or absent B-cells, CD4+ T-cell lymphopenia, and inverted CD4/CD8+ T-cell ratio [1]. Although diarrhea is the main gastrointestinal manifestation of the syndrome, in most cases no definite pathogens are identified [2]. A lack of plasma cells in the lamina propria, epithelial apoptosis, and increased IELs are characteristic histopathological findings in common variable immunodeficiency, a primary immunodeficiency similar to Good syndrome [3] [4], but not in Good syndrome. This is the first report in English describing endoscopic and pathological improvement of refractory gastrointestinal ulcers in Good syndrome by IVIG treatment. Endoscopy_UCTN_Code_CCL_1AB_2AD_3AC

16 September 2025 in Cancer Reports
Verified
Journal Article
Open access
TNTakumi Nishikawa
Takumi Nishikawa
MSMasuho Saburi
Masuho Saburi
SUShogo Urabe
Shogo Urabe
EOEiichi Ohtsuka
Eiichi Ohtsuka
Background: Richter syndrome (RS) is an aggressive transformation of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with poor prognosis. No standard treatment for RS has been established. Epcoritamab, a CD3xCD20 bispecific antibody, may offer clinical benefit.Case: An 80‐year‐old woman was diagnosed with SLL in 2017 and remained untreated for nearly 6 years. In 2023, she developed a bulky abdominal tumor. Although the initial biopsy showed SLL progression without transformation, subsequent treatments with acalabrutinib, venetoclax plus rituximab, and bendamustine plus rituximab failed. In 2024, transformation to diffuse large B‐cell lymphoma‐type RS (DLBCL‐RS) was confirmed. Two lines of cytotoxic regimens were ineffective, with rapid tumor growth. Epcoritamab was initiated as third‐line therapy. Grade 1–3 cytokine release syndrome occurred but resolved with standard management. No neurotoxicity was observed. Partial response (PR) was achieved by week 12, and the patient has maintained PR for 10 months. Infections including COVID‐19 and cytomegalovirus were managed successfully, and immunoglobulin replacement was introduced for hypogammaglobulinemia.Conclusion: This case highlights the potential of epcoritamab as an important treatment option for elderly patients with refractory DLBCL‐RS.